Suzuki R, et al. - The impact of a dipeptidyl peptidase-4 inhibitor (DPP4-i) and a sulfonylurea (SU) on daily glucose variation in patients with type 2 diabetes mellitus (T2DM) was compared. For this investigation, 53 drug-naïve Japanese patients with T2DM (HbA1c, 7.0%-9.0%; fasting plasma glucose, 6.1 mmol/L or higher) were randomized to either sitagliptin 50 mg QD or glibenclamide 2.5 mg per day (given in divided doses) in a 1:1 ratio. In drug-naïve Japanese patients with T2DM, sitagliptin had a greater ability to reduce daily glucose fluctuation than glibenclamide.